Article
KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: results from a large international multicentre study.
British journal of cancer - 16 Apr 2013
van Grieken N C T, Aoyama T, Aoyma T, Chambers P A, Bottomley D, Ward L C, Inam I, Buffart T E, Das K, Lim T, Pang B, Zhang S L, Tan I B, Carvalho B, Heideman D A M, Miyagi Y, Kameda Y, Arai T, Meijer G A, Tsuburaya A, Tan P, Yoshikawa T, Grabsch H I
Abstract excerpt
BACKGROUND: Inhibitors of the epidermal growth factor (EGFR) signaling pathway have a major role in the treatment of KRAS wild-type colorectal cancer patients. The EGFR pathway has been shown to be activated in gastric cancer (GC). However, published data on KRAS and BRAF mutation status is limited in GC and has not been compared between GC from different geographic regions. METHODS: The prevalence of KRAS and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.